• 1. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 2. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 3. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 4. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
• 5. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932

• Catalysts and Inorganic Chemicals Inorganic Compounds Homogeneous non-metal compounds Other non-metal halides

4-(Pyrrolidin-3-yl)aminobenzonitrile Hydrochloride (CAS No. 1803610-65-2): A Comprehensive Overview

4-(Pyrrolidin-3-yl)aminobenzonitrile Hydrochloride (CAS No. 1803610-65-2) is a synthetic compound that has garnered significant attention in the field of medicinal chemistry and pharmaceutical research. This compound, also known as 3-(4-cyanophenylamino)pyrrolidine hydrochloride, is a derivative of pyrrolidine and benzene, featuring a unique combination of a pyrrolidine ring and a benzene ring with a cyano group. The hydrochloride salt form enhances its solubility and stability, making it a valuable candidate for various applications in drug discovery and development.

The pyrrolidine moiety is a five-membered nitrogen-containing heterocycle that is widely used in the synthesis of bioactive compounds due to its structural flexibility and ability to form hydrogen bonds. The benzonitrile group, on the other hand, is known for its electron-withdrawing properties, which can influence the compound's biological activity and pharmacokinetic properties. The combination of these functional groups in 4-(pyrrolidin-3-yl)aminobenzonitrile Hydrochloride results in a molecule with potential therapeutic applications.

Recent studies have explored the pharmacological properties of 4-(pyrrolidin-3-yl)aminobenzonitrile Hydrochloride in various biological systems. One notable area of research is its potential as an antidepressant. Preclinical studies have shown that this compound exhibits significant antidepressant-like effects in animal models, suggesting its potential for treating mood disorders. The mechanism of action is thought to involve modulation of serotonin and norepinephrine levels in the brain, which are key neurotransmitters associated with mood regulation.

In addition to its antidepressant properties, 4-(pyrrolidin-3-yl)aminobenzonitrile Hydrochloride has also been investigated for its neuroprotective effects. Research has demonstrated that this compound can reduce oxidative stress and inflammation in neuronal cells, which are common factors contributing to neurodegenerative diseases such as Alzheimer's and Parkinson's disease. These findings suggest that 4-(pyrrolidin-3-yl)aminobenzonitrile Hydrochloride may have therapeutic potential in preventing or slowing the progression of these debilitating conditions.

The pharmacokinetic profile of 4-(pyrrolidin-3-yl)aminobenzonitrile Hydrochloride has also been studied to evaluate its suitability as a drug candidate. In vitro and in vivo experiments have shown that this compound has favorable absorption, distribution, metabolism, and excretion (ADME) properties. It exhibits good oral bioavailability and crosses the blood-brain barrier efficiently, which are crucial factors for central nervous system (CNS) drugs. These characteristics make it an attractive candidate for further preclinical and clinical development.

Safety and toxicity assessments are essential components of drug development, and several studies have been conducted to evaluate the safety profile of 4-(pyrrolidin-3-yl)aminobenzonitrile Hydrochloride. In acute toxicity studies, this compound has shown low toxicity at therapeutic doses, with no significant adverse effects observed in animal models. Chronic toxicity studies are ongoing to further investigate long-term safety and potential side effects.

The synthetic route for 4-(pyrrolidin-3-yl)aminobenzonitrile Hydrochloride involves multiple steps, including the formation of the pyrrolidine ring and the introduction of the cyano group onto the benzene ring. Recent advancements in synthetic chemistry have led to more efficient and scalable methods for producing this compound, making it more accessible for research purposes.

In conclusion, 4-(Pyrrolidin-3-yl)aminobenzonitrile Hydrochloride (CAS No. 1803610-65-2) is a promising compound with diverse pharmacological activities, including antidepressant and neuroprotective effects. Its favorable pharmacokinetic properties and low toxicity profile make it a viable candidate for further development as a therapeutic agent. Ongoing research continues to explore its full potential in various medical applications, highlighting its significance in the field of medicinal chemistry.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)